Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like Teva Announces The Launch Of Generic Vagifem In The United States July 24, 2017 Booming Bay Area Biotechs' Huge Headache: Where to House Their Employees October 12, 2017 Johnson & Johnson Quits Multibillion-Dollar Hep C Drug Program, Partners' Stocks Fall September 10, 2017
Johnson & Johnson Quits Multibillion-Dollar Hep C Drug Program, Partners' Stocks Fall September 10, 2017
